RAYONIER INC (RYN)       35.81  +0.24 (+0.67%)

35.81  +0.24 (+0.67%)

US7549071030 - REIT - After market: 35.81 0 (0%)


Fundamental Rating

3

Overall RYN gets a fundamental rating of 3 out of 10. We evaluated RYN against 218 industry peers in the Equity Real Estate Investment Trusts (REITs) industry. RYN has a great financial health rating, but its profitability evaluates not so good. RYN is valued expensive and it does not seem to be growing.




Profitability

Profitability Rating

1

RYN has a Piotroski-F score of 4.00. This indicates an average health and profitability for RYN.
RYN's Return On Assets of 2.38% is worse than the rest of the industry. The industry average Return On Assets is 4.00%.

RYN's Return On Equity of 4.56% is worse than the rest of the industry. The industry average Return On Equity is 9.25%.
RYN has a Profit Margin of 8.93%. This is below the industry average of 32.35%. 84% of the industry peers outperform RYN.
VS Industry

ROA (2.38%) VS Industry: 31% outperformed.

0.02
28.72

ROE (4.56%) VS Industry: 28% outperformed.

0.04
125.88

Profit Margin (8.93%) VS Industry: 16% outperformed.

0.16
684.56

Valuation

Valuation Rating

0

With a price book ratio of 2.89, RYN is valued correctly.
With a Price/Earnings Ratio of 68.87, RYN can be considered very expensive at the moment.
Compared to an average industry Price/Earning Ratio of 25.04, RYN is valued more expensive than its industry peers. On top of this 86% of the companies listed in the same industry are cheaper than RYN!
With a Forward Price/Earnings Ratio of 56.96, RYN is valued very expensively.

The high PEG Ratio, which compensates the Price/Earnings for growth, indicates RYN does not grow enough to justify the current Price/Earnings ratio.
Compared to an average industry price book ratio of 1.26, RYN is valued more expensive than its industry peers. 85% of the companies listed in the same industry are valued cheaper.
Compared to an average industry Enterprise Value to EBITDA ratio of 17.41, RYN is valued more expensive than its industry peers.
VS Industry

Price/Earnings (68.87) VS Industry: 14% outperformed.

320.00
0.83

Price/Book (2.89) VS Industry: 15% outperformed.

97.19
0.07

Enterprise Value/ EBITDA (21.95) VS Industry: 25% outperformed.

146.17
2.93

Growth

Growth Rating

2

The Earnings Per Share has been growing by 12.96% on average over the past 5 years. This is quite good.
RYN is expected to show a decrease in Earnings Per Share. In the coming 5 years, the EPS will decrease by -5.46% yearly.
Measured over the past 5 years, RYN shows a small growth in Revenue. The Revenue has been growing by 6.34% on average per year.
The Revenue is expected to decrease by -1.00% on average over the next 5 years.

RYN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -52.73%.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
RYN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.10%.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS12.96% 9.25% -52.73% -37.49% -21.87% -15.51% -5.46%
Revenue6.34% 10.78% -12.1% -13.91% -6.71% -4.31% -1%

Health

Health Rating

8

A Current Ratio of 3.16 indicates that RYN has no problem at all paying its short term obligations.
RYN is one of the better placed companies in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 0.76. RYN has a better rating than 89% of its industry peers.
RYN has a Quick Ratio of 2.88. This indicates that RYN is financially healthy and has no problem in meeting its short term obligations.
The Quick Ratio of RYN is much better than the industry average of 0.76. RYN has a better rating than 88% of its industry peers.

The Debt to Equity ratio of RYN is way better than the industry averages.
The Altman-Z score of RYN is much better than the industry average of 0.80. RYN has a better rating than 92% of its industry peers.
An Altman-Z score of 2.53 indicates that RYN is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Piotroski-F score of RYN is 4.00. This is a neutral score and indicates average health and profitability for RYN.
VS Industry

Debt/Equity (0.69) VS Industry: 76% outperformed.

69.38
0.00

Quick Ratio (2.88) VS Industry: 88% outperformed.

0.00
22.38

Current Ratio (3.16) VS Industry: 89% outperformed.

0.00
22.38

Altman-Z (2.53) VS Industry: 92% outperformed.

-1.25
14.35

Dividend

Dividend Rating

3

RYN's Dividend Yield is a higher than the S&P500 average which is at 2.41.
RYN has paid a dividend for at least 10 years, which is a reliable track record.
RYN has a Yearly Dividend Yield of 3.27%. Purely for dividend investing, there may be better candidates out there.

With a Dividend Yield of 3.27, RYN pays less dividend than the industry average, which is at 4.85. 81% of the companies listed in the same industry pay a better dividend than RYN!
The Dividend Rate of RYN has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
197.03% of the earnings are spent on dividend by RYN. This is not a sustainable payout ratio.
VS Industry

Dividend Yield (3.27%) VS Industry: 19% outperformed.

0.27
22.70

RAYONIER INC35.81

NYSE:RYN (1/27/2023, 7:04:00 PM)+0.24 (+0.67%)

After market: 35.81 0 (0%)

Chartmill FA Rating
GICS Sector Real Estate
GICS IndustryGroup Real Estate
GICS Industry Equity Real Estate Investment Trusts (REITs)
Earnings (Last) 11-02 2022-11-02/amc Earnings (Next) 01-31 2023-01-31
Inst Owners 84.13% Inst Owner Change 0%
Ins Owners 0.62% Ins Owner Change -0.83%
Market Cap 5.24B Analysts 50
Price Target 37.4 (4.44%)

Dividend
Dividend Yield 3.27% Dividend Growth 0.63%
DP 197.03% Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 19.79%
Min EPS beat(2) 0.26% Max EPS beat(2) 39.32%
EPS beat(4) 4 Avg EPS beat(4) 114.66%
Min EPS beat(4) 0.26% Max EPS beat(4) 397.33%
Revenue beat(2) 1 Avg Revenue beat(2) -0.55%
Min Revenue beat(2) -14.28% Max Revenue beat(2) 13.18%
Revenue beat(4) 2 Avg Revenue beat(4) 5.5%
Min Revenue beat(4) -14.28% Max Revenue beat(4) 27.06%
PT rev (1m) 0% EPS NQ rev (1m) 0%
EPS NY rev (1m) 0% Revenue NQ rev (1m) 0%
Revenue NY rev (1m) 0%

Valuation
Industry RankSector Rank
PE 68.87
Fwd PE 56.96
P/S 5.66
P/FCF 103.95
P/OCF 20.36
P/B 2.89
P/tB 2.89
EV/EBITDA 21.95
EPS(TTM) 0.52 EY 1.45%
EPS(NY) 0.63 Fwd EY 1.76%
FCF(TTM) 0.34 FCFY 0.96%
OCF(TTM) 1.76 OCFY 4.91%
SpS 6.32 BVpS 12.38
TBVpS 12.38 PEG (NY) N/A
PEG (5Y) 5.31

Profitability
Industry RankSector Rank
ROA 2.38%
ROE 4.56%
ROIC 3.52%
ROICexc 3.82%
ROICexgc 3.82%
OM 14.64%
PM 8.93%
GM 21.73%
ROICexgc(3y) 4.43% ROICexcg growth 3Y 8.45%
ROICexcg growth 5Y -3.2% ROICexc(3y) 4.43%
ROICexc growth 3Y 8.45% ROICexc growth 5Y -3.2%
OM growth 3Y 3.57% OM growth 5Y -5.39%
PM growth 3Y 3.16% PM growth 5Y -11.95%
GM growth 3Y 3.02% GM growth 5Y -4.46%
F-Score 4 Asset Turnover 0.27

Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 24.94
Debt/EBITDA 4.43
Cap/Depr 139.28%
Profit Quality 61.02%
Current Ratio 3.16
Quick Ratio 2.88
Altman-Z 2.53
F-Score 4 WACC 7.04%
ROIC/WACC 0.54 Cap/Depr(3y) 126.67%
Cap/Depr(5y) 141.9% Profit Quality(3y) 121.34%
Profit Quality(5y) N/A

Growth
EPS 1Y -52.73% EPS 3Y 9.25%
EPS 5Y 12.96% EPS growth Q2Q -71.7%
EPS Next Y -37.49% EPS Next 2Y -21.87%
EPS Next 3Y -15.51% EPS Next 5Y -5.46%
Revenue growth 1Y -12.1% Revenue growth 3Y 10.78%
Revenue growth 5Y 6.34% Revenue growth Q2Q -46.46%
Revenue Next Year -13.91% Revenue Next 2Y -6.71%
Revenue Next 3Y -4.31% Revenue Next 5Y -1%
EBIT growth 1Y -46.15% EBIT growth 3Y 14.74%
EBIT growth 5Y 0.61% EBIT Next Year 56.37%
EBIT Next 3Y 15.17% EBIT Next 5Y 10.12%
FCF growth 1Y 26.42% FCF growth 3Y -28.33%
FCF growth 5Y N/A OCF growth 1Y 36.92%
OCF growth 3Y 1.59% OCF growth 5Y 9.79%

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA